The main objective of this prospective, observational, long-term follow-up (LTFU) study is to evaluate the long-term safety profile of the gene therapy products evaluated by Krystal Biotech, Inc. which have a shared backbone of HSV-1, in participants who received at least one dose of investigational product (IP).
Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.
Krystal Biotech (KRYS) is the sponsoring company for this trial. BiotechSign currently grades this company F (29/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.